Stanford University
Showing 381-390 of 2,393 Results
-
Caitlin Contag
Clinical Scholar, Medicine - Pulmonary, Allergy & Critical Care Medicine
Postdoctoral Scholar, Pulmonary and Critical Care MedicineCurrent Research and Scholarly InterestsEmerging pathogens, high-consequence pathogens, critical care in resource limited settings, early interventions for sepsis, marginalized patient populations, sexually transmitted diseases, planetary health
-
Marimar Contreras Nieves
Clinical Scholar, Medicine - Nephrology
Postdoctoral Scholar, NephrologyBioI am currently in my second year of nephrology fellowship, working on a Masters in clinical research and epidemiology, and also doing postdoctoral research on a U2C-TL1. During my training I have worked on clinical research focused on environmental risk factors and health care barriers that can initiate or accelerate the development and progression of kidney disease. My goal is to reach disadvantaged populations and help reduce the gaps in health that may stem from their vulnerability to determinantal environmental exposures. My projects have included investigating chronic kidney disease of uncertain etiology, with particular interest in California’s Central Valley.
-
John P. Cooke, MD, PhD
Professor of Medicine (Cardiovascular Medicine), Emeritus
Current Research and Scholarly InterestsOur translational research program in vascular regeneration is focused on generating and characterizing vascular cells from human induced pluripotential stem cells. We are also studying the therapeutic application of these cells in murine models of peripheral arterial disease. In these studies we leverage our longstanding interest in endothelial signaling, eg by nitric oxide synthase (NOS) as well as by nicotinic cholinergic receptors (nAChR).
-
Allen Cooper
Professor of Medicine (Gastroenterology and Hepatology), Emeritus
Current Research and Scholarly InterestsI have had a long standing interest in the liver's role in cholesterol and lipid metabolism. In the past this was focused on laboratory studies but currently involves human studies as part of my patient care responsibilities. In particular I am interested in the role of NAFLD (non-alcoholic fatty liver disease) in patients with Hepatitis C aand in post liver transplant patients.
-
Joseph David Cooper
Clinical Assistant Professor (Affiliated), Medicine - Med/Infectious Diseases
BioJoseph David Cooper attended Bucknell University for his undergraduate degree with a dual major in Biology and Philosophy. He graduated from St. George’s University School of Medicine and went on to complete his Internal Medicine residency at Geisinger Medical Center in Danville, Pennsylvania. He remained at Geisinger for an additional year as Chief Resident in Internal Medicine with a focus on teaching and the education of trainees. He completed his Infectious Diseases fellowship at Montefiore Medical Center-Albert Einstein College of Medicine in the Bronx, New York. He is board certified in both Internal Medicine and Infectious Disease.
He began working at Santa Clara Valley Medical Center primarily in the PACE (Partners in AIDS Care and Education) and Infectious Diseases Clinics in July 2019. He has an active outreach HIV clinic at Valley Health Center in Gilroy, California once a month which maintains a regional presence for excellence in HIV care. He sees outpatients with general infectious diseases and provides inpatient infectious diseases consultation at Santa Clara Valley Medical Center, the main quaternary referral hospital for the Santa Clara Valley Healthcare system. He is actively involved in the teaching and training of Stanford University Infectious Diseases fellows, Internal Medicine residents from his home institution and Kaiser Permanente Santa Clara. Dr. Cooper holds an appointment of Clinical Assistant Professor (Affiliated) at Stanford University School of Medicine in the division of Infectious Diseases & Geographic Medicine and department of Medicine since 2020.
Dr. Cooper is an active member of the American College of Physicians, WikiGuidelines (PWID and Bacteremia guidelines), Infectious Diseases Society of America, and HIV Medicine Association. He volunteers his time and energy within these international professional organizations previously serving on workgroups surrounding education, mentoring of trainees and as an ad hoc reviewer for infectious diseases and general internal medicine journals. His professional interests are broad and include HIV/AIDS, opportunistic infections, sexually transmitted infections, with a special interest in mycology and fungal infections. He is widely published in a variety of academic journals collaborating with colleagues in all parts of the world. Administratively, Dr. Cooper has held numerous leadership positions, previously serving as Associate Medical Director of the PACE Clinic from 2021 to 2023. Currently, Dr. Cooper holds a leadership position serving on the executive board of Valley Physicians Group (VPG), an organization representing over 400 physicians, dentists and podiatrists at his current institute, focusing on physician advocacy, excellence and organization. Dr. Cooper is passionate about providing high quality, evidence-based care to people living with HIV and AIDS. He uses his professional expertise, passion and energy to ensure that his patients remain as well and healthy as possible.
Outside of medicine and work, you can find Dr. Cooper spending time with his wife and two daughters - hiking and exploring the Bay Area and beyond, listening to all types of music with a particular interest in live music, gardening, nature photography, cooking new recipes, exercising and playing sports. -
Steven M. Corsello
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly InterestsOur laboratory operates at the intersection of functional genomics and chemical biology, with the goal of advancing novel molecular mechanisms of cancer inhibition to clinical use. We aim to 1) leverage phenotypic screening and functional genomics to determine novel anti-cancer mechanisms of small molecules, 2) develop new targeted therapy approaches against solid tumors, and 3) build a comprehensive community resource for drug repurposing discovery.
